The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity. T...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2015-10-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/7530
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!